Webshop
The next generation biopharmaceuticals
Products
Please note!
The webshop will be closed between July 8 and August 5.
Happy summer!
// Team Affibody
Imaging agents
| Affibody® Research Reagent | Catalog number | Size | Price |
|---|---|---|---|
Anti-EGFR imaging agent |
10.2023.01.0005 |
500 µg |
€ 715 |
Anti-EGFR imaging agent |
10.2023.01.0001 |
100 µg |
€ 170 |
Anti-HER2, imaging agent |
10.1861.01.0001 |
100 µg |
€ 315 |
Anti-HER2, imaging agent |
10.1861.01.0005 |
500 µg |
€ 1 455 |
Imaging agent negative control |
10.2046.01.0005 |
500 µg |
€ 465 |
EGFR
| Affibody® Research Reagent | Catalog number | Size | Price |
|---|---|---|---|
Anti-EGFR unconjugated |
10.1886.01.0001 |
100 µg |
€ 170 |
Anti-EGFR unconjugated |
10.1886.01.0005 |
500 µg |
€ 465 |
Anti-EGFR, fluorescein conjugated |
10.1886.03.0001 |
100 µg |
€ 465 |
Anti-EGFR, agarose immobilized |
10.1246.04.0002 |
200 µl |
€ 550 |
Anti-EGFR, IP kit |
10.1246.04.9002 |
200 µl |
€ 615 |
HER2
| Affibody® Research Reagent | Catalog number | Size | Price |
|---|---|---|---|
Anti-HER2, unconjugated |
10.0817.01.0001 |
100 µg |
€ 170 |
Anti-HER2, unconjugated |
10.0817.01.0005 |
500 µg |
€ 465 |
Anti-HER2, biotin conjugated |
10.0817.02.0001 |
100 µg |
€ 465 |
Anti-HER2, fluorescein conjugated |
10.0817.03.0001 |
100 µg |
€ 465 |
Anti-HER2, agarose immobilized |
10.0817.04.0002 |
200 µl |
€ 550 |
Anti-HER2, IP kit |
10.0817.04.9002 |
200 µl |
€ 615 |
Anti-HER2, HRP conjugated |
10.0817.05.0002 |
200 µl |
€ 465 |
HSA
| Affibody® Research Reagent | Catalog number | Size | Price |
|---|---|---|---|
Anti-HSA, unconjugated |
10.0644.01.0010 |
1 mg |
€ 715 |
Anti-HSA, unconjugated |
10.0644.01.0050 |
5 mg |
€ 2 495 |
Anti-HSA, biotin conjugated |
10.0644.02.0005 |
500 µg |
€ 715 |
IgA
| Affibody® Research Reagent | Catalog number | Size | Price |
|---|---|---|---|
Anti-IgA, unconjugated |
10.1150.01.0005 |
500 µg |
€ 395 |
Anti-IgA, unconjugated |
10.1150.01.0050 |
5 mg |
€ 2 495 |
IgE
| Affibody® Research Reagent | Catalog number | Size | Price |
|---|---|---|---|
Anti-IgE, unconjugated |
10.0816.01.0010 |
1 mg |
€ 715 |
IgG
| Affibody® Research Reagent | Catalog number | Size | Price |
|---|---|---|---|
Anti-IgG, unconjugated |
10.0623.01.0010 |
1 mg |
€ 715 |
Anti-IgG, unconjugated |
10.0623.01.0050 |
5 mg |
€ 2 495 |
Anti-IgG, biotin conjugated |
10.0623.02.0005 |
500 µg |
€ 715 |
IgM
| Affibody® Research Reagent | Catalog number | Size | Price |
|---|---|---|---|
Anti-IgM, unconjugated |
10.1329.01.0005 |
500 µg |
€ 465 |
Anti-IgM, unconjugated |
10.1329.01.0050 |
5 mg |
€ 2 495 |
Insulin
| Affibody® Research Reagent | Catalog number | Size | Price |
|---|---|---|---|
Anti-Insulin, unconjugated |
10.0814.01.0010 |
1 mg |
€ 715 |
Anti-Insulin, unconjugated |
10.0814.01.0050 |
5 mg |
€ 2 495 |
TNF-α
| Affibody® Research Reagent | Catalog number | Size | Price |
|---|---|---|---|
Anti-TNF-α, unconjugated |
10.0841.01.0010 |
1 mg |
€ 715 |
Anti-TNF-α, unconjugated |
10.0841.01.0050 |
5 mg |
€ 2 495 |
Anti-TNF-α, agarose immobilized |
10.0841.04.0002 |
200 µl |
€ 465 |
Anti-TNF-α, IP kit |
10.0841.04.9002 |
200 µl |
€ 595 |
Transferrin
| Affibody® Research Reagent | Catalog number | Size | Price |
|---|---|---|---|
Anti-Transferrin, unconjugated |
10.1105.01.0005 |
500 µg |
€ 465 |
Anti-Transferrin, unconjugated |
10.1105.01.0050 |
5 mg |
€ 2 495 |
Fibrinogen
| Affibody® Research Reagent | Catalog number | Size | Price |
|---|---|---|---|
Anti-Fibrinogen, unconjugated |
10.1278.01.0005 |
500 µg |
€ 465 |
Anti-Fibrinogen, unconjugated |
10.1278.01.0050 |
5 mg |
€ 2 495 |
Affibody
| Affibody® Research Reagent | Catalog number | Size | Price |
|---|---|---|---|
Goat Anti-Affibody® IgG |
20.1000.01.0005 |
500 µl |
€ 395 |
Affibodys latest Press releases
2019-07-16
Affibody Announces Interim Analysis in Phase 2 Psoriasis Trial of ABY-035
Affibody in short
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Upcoming reports Financial calendar
- Interim Report Q1 (May 17, 2019)